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Abstract: 
Candida albicans is one of the most common fungal pathogens associated with opportunistic 
and nosocomial infections. Infection is often initiated through formation of a biofilm, which is 
also drug resistant. A recently discovered small molecule called filastatin shows some promise 
as an inhibitor of biofilm formation and adhesion to polystyrene. A high-throughput screening 
assay was performed using a deletion mutant library in order to determine the functional 
pathway of filastatin. Results indicate that our drug may play a role in disrupting the iron 
metabolism pathway, particularly through genes regulated through Hap43 and Rim101. 
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Introduction: 
Mycosis caused by opportunistic fungi has been observed at increasing rates in recent 
years especially in immuno-compromised patients. Strains of the genus Candida account for 8 -
10% of all nosocomial blood stream infections acquired in the hospital setting (M. A. Pfaller, 
2007). The number of reported cases and deaths caused by nosocomial bloodstream infections 
has steadily increased by over 5,000 between 1980 and 1997 (M. A. Pfaller, 2007). In the United 
States, it has been observed that mycoses caused by species from the genus Candida are the 
fourth most common nosocomial blood stream infection. It has been estimated that between 
7,000 and 28,000 cases of invasive candidiasis occur annually and for 40% of these patients, the 
infection is deadly (M. A. Pfaller, 2007). Thus, it is of great importance to the scientific and 
medical community to better understand the virulence strategies for Candida, in order to 
mitigate or combat nosocomial infections.    
The most prevalent fungal pathogen from the Candida genus is Candida albicans (Figure 
1) (U.S. Centers for Disease Control and Prevention, 2013). C. albicans is a polymorphic, 
opportunistic fungal pathogen that can cause systemic infections with high mortality rates and 
can also cause mucosal conditions such as thrush in immunocompromised patients and 
vaginitis (Mayer, Wilson, & Hube, 2013). The fungus is present as a commensal in the human 
epithelial lining of the gastrointestinal tract, mouth, uro-genital tract without negatively 
affecting the host. However, when the patient’s immune system is compromised such as in 
neonates or infection with HIV, the fungus causes infections on the superficial region of the 
body, or in rarer cases, lead to life threatening systemic infections.  (Mayer, Wilson, & Hube, 
2013).  
 
  
  
  
 
 
 
 
 
 
 
The fungus is dimorphic, and can switch growth between yeast or hyphal growth (Figure 
1) depending on environmental conditions. The hyphae are a straight, parallel-walled 
filamenting form of C. albicans which is considered to be more invasive and is speculated to 
cause tissue penetration during infection. The yeast form of C. albicans grows at low pH and is 
characterized by oval shaped cells that typically bud off at hyphal nodes.  These planktonic cells 
are thought to be important for establishing infection at secondary locations.  This 
morphological plasticity allows C. albicans to survive in a variety of environments and 
conditions such as adverse pH within a phagocyte or serum in the blood stream (Sudbery, Gow, 
& Berman, 2004).  This also allows C. albicans to be a versatile pathogen, and is important for 
Figure 1: C. albicans, poses a significant 
public health threat due to drug-
resistance (U.S. Centers for Disease 
Control and Prevention, 2013),  
virulence. Therefore, mutants that are unable to switch between morphological states are 
avirulent.  
Another powerful virulence strategies and reason that C. albicans infections are so 
prevalent in the medical setting is the formation of biofilms (Heitman, 2012). Biofilms are the 
formation of yeast/hyphal cell matrix that gives the grouping a heightened form of protection 
from antimicrobial agents and host immune factors. To initiate the formation of a biofilm, first 
cells must adhere to the surface. Then proliferation of yeast cells occurs along with hyphae, 
which eventually escalates into an extracellular matrix (Heitman, 2012).  These factors tend to 
form on a variety of different biotic or abiotic settings alike. In the medical setting this typically 
refers to objects such as catheters and other medical equipment. Since the fungus present in 
biofilms exhibits more resilience to antimicrobials and sterilization, the possibility of infecting 
patients is high in the medical setting. In addition, these biofilms exhibit resistance to antifungal 
drugs (Zhihong Xie, 2012), making them harder to treat than other types of fungal infections in 
patients. The biofilm extracellular matrix is also been linked to the resistance to neutrophils by 
preventing activation of reactive oxygen species (ROS) in the host (Zhihong Xie, 2012). The 
release of ROS is necessary for the destruction of pathogens by phagocytes and recruiting of 
more phagocytes to the site of infection.  This study also speculates that β- glucans, an essential 
component of the extracellular matrix protects C. albicans from degradation by the immune 
system (Zhihong Xie, 2012). Therefore, biofilms are a strong virulence factor because they 
promote attachment to biotic and abiotic surfaces and render the microbial community drug 
resistant.  
Many studies have been done to understand how to prevent and neutralize 
opportunistic Candida albicans infections. One issue that is prevalent when developing 
antifungal agents is that because of its eukaryotic characteristics, it is hard to find specific 
targets that do not exhibit a homolog with humans. The main target that most antifungal drugs 
utilize today targets the cell membrane (Azole class of drugs and amphotericin B) or cell wall 
(caspofungin) of the fungus. The two main targets are ergosterol or β-D-glucan, which are both 
key components for C. albicans. Ergosterol is targeted because it is considered a main 
component of fungal membranes, although its similarities to cholesterol make some antifungals 
toxic at high concentrations. The advantage to β-D-glucan is that it is essential to the cell wall of 
C. albicans but is not present in humans, lowering the risk of toxicity (Cowen & Steinbach, 
2008). It has been the human immune system recognizes β-glucan via Dectin-1 receptors on the 
surface of macrophages (Brown, et al., 2002). Though β-glucan is usually expressed in high 
quantities in Candida, it is hidden by a layer mannoprotein that shields the molecule from 
Dectin-1 receptors. It has been shown that subinhibitory concentrations of capsofungin, a 
common anti-fungal drug, are capable of exposing Candida’s β-glucan layer. This is turn is 
capable of producing a stronger immune response so it is possible that this method may be 
considered as a novel treatment for C. albicans infections (Wheeler & Fink, 2006).       
Potential Vaccine Strategies 
Researchers have also begun targeting the adhesion system of C. albicans in hopes of 
preventing many nosocomial C. albicans infections. The adhesion system of C. albicans is based 
on two different tactics known as induced endocytosis and active penetration. Induced 
endocytosis operates by the expression of proteins on the surface of the C. albicans that cause 
the host’s ligands to engulf the fungal cell, thereby bringing it into the host cell. It has been 
demonstrated that even dead hyphae cells are engulfed, indicating that induced endocytosis of 
fungus does not need viable cells, but is linked to proteins created before death (Dalle, et al., 
2010). It is speculated that induced endocytosis is mediated by Als3 and Ssa1.  The other form 
of adhesion, active penetration, is not a fully understood mechanism. However, it is postulated 
to operate by physical force of the hyphae in order to digest part of the hosts’ cellular 
membrane and use the hole created as an entry way into the system (Mayer, Wilson, & Hube, 
2013). It has been shown that vaccination with the recombinant N-terminus of the Als3 and 
related Als1 proteins protects mice against oropharyngeal, vaginal and disseminated candidiasis 
(Spellberg, et al., 2006). These vaccines also appear to induce both broad antibody and cell-
mediated immune responses and thereby appear to provide adequate protection against 
Candida infections. Therefore, targeting adhesion proteins of Candida may be a viable target 
for vaccines and therapeutics (Spellberg, et al., 2006).  
The value of a prophylactic drug in preventing nosocomial infections has already been 
seen in earlier studies that have examined whether antifungal treatment reduces the risk of 
Candida infection in patients. In patients suffering recurrent gastrointestinal leakages, for 
example, only 8% of patients treated with fluconazole developed a Candida infection while as 
many as 31% of placebo-treated patients became infected. In addition, a study on patients 
intentionally colonized with Candida showed that infection only persisted in approximately 30% 
of fluconazole-treated patients while 70% of placebo treated patients developed infections. 
Lastly, it was shown that Candida colonization rates in liver transplant patients receiving 
prophylactic fluconazole decreased from 70% to 28% in comparison to those that received a 
placebo. Most importantly, it was observed that mortality rate greatly decreases from 13% to 
2% with prophylactic treatment (Snydman, 2003). Therefore, this study suggests that antifungal 
drugs have the capability to prevent Candida infections when administered prophylactically.  
Drug Resistance  
Though the use of antifungal agents as prophylactics has been shown to be effective, 
there is concern among some researchers that the overuse of azole drugs may lead to an 
increase in prevalence of other Candida species. For example, the use of fluconazole as a 
prophylactic has been correlated with a decrease in the incidence of C. albicans and C. 
tropicalis. However, this decrease coincided with an increase in prevalence of C. glabrata and C. 
krusei, which are more difficult to treat. Therefore, it is feared that the continued use of 
fluconazole as a prophylactic will lead to more-resistant and pathogenic strains becoming more 
prevalent. To prevent this, it has become necessary for health care workers to administer 
antifungals only to patients that stand to benefit the most from prophylactic treatment. 
Regardless, there is a growing need for the development of new antifungal agents in order to 
stem the proliferation of azole resistant fungi (Snydman, 2003). 
 
Functional Drug Screen to Identify Small Molecules that Prevent Attachment to Plastics 
Previous research has been done on the inhibition of C. albicans binding to plastics, 
which is a major cause of biofilm formation in health care settings. C. albicans has been shown 
to bind very strongly to polystyrene plastics (Mitchell & Nobile, 2006). Our laboratory recently 
reported identification of filastatin, which inhibits adhesion of C. albicans to polystyrene 
surfaces, surgical silicone mesh, and also to cultured human epithelial cells (Fazly, et al., 2013). 
As can be seen in Figure 2 below, C. albicans is capable of binding to silicone elastomers in the 
presence of DMSO. However, in the presence of filastatin, C. albicans loses its ability to bind to 
the mesh. The strain edt1 was used as a positive control in this experiment due to the fact that 
it lacks an adhesion protein needed for the fungi to bind to surfaces.  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
Filastatin has the potential to be widely used as a prophylactic coating material for 
medical devices because abiotic surfaces coated with filastatin are resistant to colonization by 
fungal biofilm (Fazly, et al., 2013).  
Figure 2: Adhesion 
of C. albicans to 
Silicone Elastomers 
(Fazly, et al., 2013) 
Filastatin was identified from a library of 30,000 small molecules for inhibition of 
adhesion of C. albicans (strain SC5314) to polystyrene. The strain edt1-/-, which lacks a cell wall 
adhesion protein served as a positive control while SC5314 cells in the presence of DMSO alone 
served as a negative control. The research group then tested the ability of the filastatin to 
inhibit the binding of a GFP-expressing Candida strain to monolayers of human epithelial A549 
cells. Of all of the compounds tested, it was found that filastatin was the best inhibitor of 
adhesion to human epithelia based on its ability to inhibit the filamentation of Candida 
albicans. Additionally, it was found that filastatin was not significantly toxic to human cells, 
even at concentrations as high as 250 μM. Therefore, this compound shows promise as a drug 
or prophylactic to fight Candida infections due to its ability to inhibit the fungi’s adhesion to 
both polystyrene and human cells. The chemical structure of filastatin can be seen below in 
Figure 3 (Fazly, et al., 2013).  
  
 
  
 
 
 
 
 
 
 
 
Figure 3: Chemical Structure 
of Filastatin (Fazly, et al., 
2013). 
Because of these potential clinical applications, the effect that filastatin had on Candida 
that was already bound to polystyrene was tested. It was found that filastatin did, in fact, 
reduce the number of Candida cells bound to polystyrene; however, it was more effective in 
this capacity when the drug and fungi were added at the same time and coincubated. 
Regardless of when the drug is added, these results indicated that filastatin could be effective 
against biofilms. Furthermore, additional experiments showed that filastatin was effective at 
inhibiting adhesion of three other pathogenic Candida strains: C. dubliniensis C. tropicalis, and 
C. parapsilosis (Fazly, et al., 2013).  
The drug’s potential use as a prophylactic against the formation of Candida biofilms on 
implanted medical devices was then tested by measuring colony formation on surgical silicone 
elastomers. It was observed that wild type Candida failed to form biofilms and instead 
remained dispersed in media in the presence of filastatin in both carbon-deficient Spider media 
and mammalian serum at low concentrations. These facts could have major clinical 
implications; fungal biofilms on medical devices lead to thousands of systemic and potentially 
life-threatening fungal infections per year. Therefore, a prophylactic drug that prevents biofilm 
and hyphal formation is capable of greatly reducing nosocomial Candida infections (Fazly, et al., 
2013).  
Lastly, this paper demonstrated that our drug of interest is capable of inhibiting fungal 
growth and infection in a variety of systems in vivo. When treated with filastatin, it was found 
that the number of C. elegans nematodes exhibiting the DAR phenotype caused by C. albicans 
infection decreased by approximately thirty percent. Furthermore, filastatin treatment was 
found to extend the life-span of C. elegans that had been previously infected. In addition, the 
researchers found that individual yeast cells predominated in vulvovaginal candidiasis in mice 
that had been treated with filastatin. Therefore, this suggests that filastatin is capable of 
preventing hyphae and biofilm formation ex vivo. This finding is significant because of the 
number of women infected with vulvovaginal infections; 75% of women will suffer from 
vulvovaginal candidiasis at some point in their lifetime, with as many as 95% of these infections 
being caused by C. albicans in particular (Fazly, et al., 2013).  
The focus of our project is to identify the biological target of filastatin in C. albicans, 
which would allow for a better understanding of its mechanism. We will use loss-of-function 
reverse genetics approaches to identify potential targets of filastatin by screening a C. albicans 
homozygous deletion library using the adhesion assay described previously (Noble, et al., 2010). 
In short, loss of target gene function is expected to mimic filastatin treatment and prevent 
attachment of C. albicans to plastic surfaces as shown in Error! Reference source not found. 
below. Therefore, mutants that lack the drug target will not show an altered phenotype in 
when treated with filastatin (Error! Reference source not found. green). Additionally, it was 
hypothesized that filastatin might have multiple targets (Fazly, et al., 2013).  Such genes are 
also likely to be identified in this screen as mutants that show a synergistic effect upon 
treatment with filastatin. The identity of the target gene will be confirmed by complementing 
the deletion mutant by replacing a single copy of the gene at a chromosomal location.  The 
complemented heterozygous strain is predicted to restore the ability of the mutant to adhere 
to plastic.   
The library will be tested on polystyrene plates through a crystal violet assay, to 
determine susceptibility to filastatin and how adhesion is affected by different deletion 
mutations. As shown in Error! Reference source not found., two different types of phenotype s 
would be the most ideal to discover. 
 
Figure 4: Expected Adhesion Patterns of Mutants to Filastatin 
 
Before mutants showing significance are further studied, the phenotype being observed will be 
shown to be a result of the intended deletion. To do this, reverse complementation will take 
place by replacing a single copy of the deletion gene back into the chromosomal location. The 
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Mutation in TARGET gene(s) 
NO response to Filastatin 
complemented strain should rescue the mutant phenotype and phenocopy the wild type by 
restoring adhesion to plastic surfaces. This will allow for the mutant to be used for testing with 
model in vitro/ in vivo assays such as C. elegans or mitochondria. The end conclusion will help 
give a greater understanding of how filastatin affects C. albicans and give a greater 
understanding of the underlying mechanisms that help prevent adhesion.  
  
Materials and Methods 
Primary Screening 
 
For the primary screen, single colonies were picked and inoculated into 5 mL cultures of 
SC+ 0.15% glucose media and grown overnight in a rotating wheel. The OD of the cultures was 
then measured at OD600nm. Cultures were spun down and resuspended in fresh SC +0.15% 
glucose to a final concentration of 0.5 OD/mL. 200 uL of 0.5 OD/mL C. albicans strains were 
pipetted onto 96 well flat-bottom polystyrene plates. Filastatin or DMSO was added to cultures 
at appropriate concentrations, never exceeding 1% DMSO. Plates were covered with aluminum 
foil and incubated at 37 degrees for 4 hours. After 4 hours of incubation, plates were decanted 
and 40 uL of 0.5 % Crystal Violet Dye was added to each well. The plates were covered and left 
at room temperature to incubate for 45 minutes. Plates were then decanted and washed by 
submersion 10 times in an ice bucket filled with dH20, changing the water every 5 washes. 
Plates were tapped onto a paper towel to remove residual dH20 and 200 uL of 75% MeOH was 
added to each plate and incubated at room temperature for 30 minutes. The plates were then 
read at 590 nM to detect relative crystal violet fluorescence.  
 
Data analysis  
    The primary screening was analyzed using Microsoft Excel. All data was normalized to the 
wild type (SN250). If a mutant exploited RFU that was two times the standard deviation either 
higher or lower than that of the wild type and then did not show a change in adhesion with the 
addition of filastatin, it was considered a hit.  
 PCR Design 
    PCR primers were designed for Hap43 and Rim101, using the IDT primer design application. In 
order to confirm full integration of gene, amplicons were designed to have 100-200 bp 
overhangs on both sides of the gene. The amplicon was also designed to complement 20 bp of 
PS105 plasmid (Hap43: F= 5’-GTAAATTACAATTGGTATTTTCAACCAATATT 
ACCACACCAACTAGCCACGTCGTTCC-3’ R= 5’-CTATCTCTCTTTTTTTTGCCCATTTGAGTTAG 
TGCATGACGATGCAGATGACGCGGATTC-3’, Rim101: F= 5’ - GTAAATTACAATTGGTAT 
TTTCAACCAATATTACCACACTGGCAATCAATTCCCAGACA03; R=5’ ATCTCTCTTTTTTTTGCCCATTTGA 
GTTAGTGCATGACAGAGACCGGTAACACTACTTTC-3’). Long amp polymerase was used for all PCR 
reactions. For confirmation of insertion back into C. albicans, primers were designed to check 
for the insertion into the genome. Primers were designed to aplify a small region of the 5’ 
region of the mutant of interest and also amplify the arginene resistant gene (Hap43: F= 5’ - 
CTACACCAAAGTGATCCCACA-3’ R= 5’ - CATCACTTGACGTGGCATTATC-3’, Rim101: F= 5’ -ATTACC 
ACACTGGCAATCAATTC-3’, R= 5’ CTCTCACTTGCACCGGTATT-3’).  
Complementation analysis 
One colony of S. cerevisiae was picked and inoculated into 3 mL of YPD media and 
incubated at 30 C overnight in a tube roller. The next morning, 1.5 mL of cultures were used to 
inoculate 50 mL of fresh YPD media and grown in a shaker at 30 C until OD600 1-1.5 was met. 
The culture was then centrifuged at 3000 rpm for 5 minutes at room temperature and washed 
with 5 mL LiOAC mix (1x TE ph 8, 100 mM lithium acetate). This mixture was then centrifuged at 
3000 rpm for 5 minutes and the pellet was resuspended in 1 mL LiOAC. 100 uL of washed cells 
was then mixed with 10 uL single strand DNA carrier and 5 uL of the PCR product being used for 
gap repair. Then 500 uL of the PEG Mix (1x TE ph 8, 100 mM lithium acetate, 40 % PEG 3350) 
was added into the solution. The mixture was mixed well by pipetting and incubated for 30 
minutes at room temperature. The mixture is then heat shocked at 42C for 5 minutes and 
centrifuged at approximately 3600 rpm for 3 minutes. The PEG mixture was decanted and the 
cells were washed with 0.5 mL YPD. The pellet was then resuspended in 100 uL of ddH20 and 
plated on selective media. The mixture was grown for 48 hours at 30 C. To confirm integration 
of gene of interest into plasmid, conformational PCR was run after plasmid purification.   
 
High Efficiency Electrotransformation of E. coli 
The competent E. coli cells were thawed on ice and then 40 uL of the cell suspension 
and 5 uL of purified plasmid from previously described gap repair transformation were placed 
into a pre-chilled 1.5 mL microfuge tube, gently mixing with pipette tip (do not mix by pipetting 
up and down). The mixture was allowed to incubate on ice for approximately one minute. The 
cells were transferred to a cold electroportion cuvette and the MicroPulser was set to “Ec2”. 
The cuvette was then placed into the chamber slide, were it is seated between the contacts in 
the base of the chamber. One pulse was administered and then 1 mL of SOC medium was 
immediately added to the cuvette and gently resuspended with a Pasteur pipette. The cells 
were then transferred to a microfuge tube and incubated at 37 C for 1.5 hours shaking at 225 
rpm. Then 100 uL of cell suspension was plated onto LB+AMP plates and incubated overnight at 
37C. The plasmid was purified using the qiagen mini-prep plasmid purification strategy and 
stored for later use at -20C.  
 
Transformation of C. albicans  
One colony of the knockout C. albicans strain of interest was grown in 5 mL of YPD 
overnight at 30 C in a rotating wheel. The following morning 1.5 mL of the overnight culture 
was inoculated into 50 mL of fresh YPD media and incubated in a 30 C shaker for 5-6 hours until 
the OD600 reaches between 0.5 -1. The culture was then centrifuged for 2 min at 1000g and the 
supernatant was discarded. The cells were then resuspended at 900 uL LiOAC/TE and 
transferred to a microcentrifuge tube. The mixture was then pelleted for 1 minute at 1000g, 
followed by two more washes with 900 uL LiOAC/TE, to be finally resuspended in 400 uL 
LiOAC/TE. In a separate microfuge tube, the following reagents were mixed. First 10 uL of 
10mg/mL Herring sperm (or Salmon sperm) DNA was administered after being denatured by 
boiling for 2 minutes and then snap cooled on ice. Then 1 ug (20-50 uL of digested plasmid) to 
be transformed into C. albicans genome was added into the solution. Followed by 200 uL 
washed cells in LiOAC/TE and 1 mL PEG mix. This mixture was incubated overnight at room 
temperature while inverting.. The mixture was then heat shocked at 42C for 1 hr the following 
morning and pelleted for 1 minute at 1000g. The supernatant was discarded and the pellet was 
washed with 1 mL sterile water. The pellet was resuspended in 150 uL ddH20 and plated on 
YNB-ARG media. The plates were allowed to incubate at 30 C for 2-3 days to allow for the 
growth of colonies. Genomic integration was confirmed by running conformational PCR analysis 
and confirmation of prospective phenotype. 
Colony morphology Assay 
    Mutants of interest and wild type (C. albicans SN250) were grown overnight in SC+ AA+ 
0.15% glucose. Culture concentrations were measured at OD600 nm. The cultures were then 
spun down at 3000 rpm and resuspended in ddH20 to give a final concentration of 1 OD. A 96 
well plate was used to make a series of 10-fold serial dilutions using ddH20. Then 5 uL of the 
dilutions were incubated at 37 C on solid Spider media for six days.  
Sensitivity Assay 
    Mutants of interest and wild type (C. albicans SN250) were grown overnight at 30 C in 
SC+AA+ 0.15% glucose. Cultures were spun down at 3000 rpm and resupsended in ddH20 to 
give a final concetration of 1 OD. A 96 well plate was then used to make a series of 10-fold 
serial dilutions using ddH20. Then 5 uL of the dilutions were incubated at 30 C on SC+ 1 mM 
CuSO4 + AA+ glucose agar plates and incubated overnight at 30 C.  
 
  
Results: 
Primary Screening 
           In this MQP, a reverse genetic screen was performed using a knockout mutant library 
(Noble, et al., 2010). To gain a better understanding of how the anti-adhesion compound 
filastatin decreases the ability of the pathogen Candida albicans to adhere to plastic surfaces, 
mutants were allowed to form biofilms on a polystyrene surface of a 96 well plate.  Biofilms 
were treated with filastatin or the carrier DMSO and stained with crystal violet to visualize 
adhesion.  
Data Analysis 
    The mutants were analyzed with the use of Microsoft excel and normalized to the wild type, 
which was present on every plate. After normalization took place, the mutant was compared to 
the wild type and if it was greater or less than 2 times the standard deviation, it went onto the 
next round of analysis. If the change in adhesion was less than 10%, the mutant was added as a 
hit. An example of a non hit v. both versions of a hit (more adhesive and less adhesive) can be 
seen below in figure 5.  
               Figure 5: Example of hit for lower and higher adhesion in Crystal Violet assay 
 
Out of the ~650 mutants surveyed, 42 of the mutants were identified as potential 
targets, or pathways that regulate targets of filastatin. This list of 42 hits constituted to be 
approximately 6% of all total mutants screened.  Out of the forty two putative mutants, fifteen 
resulted from mutants that showed higher adherence to the polystyrene plates than the wild 
type and twenty seven of the hits resulted in mutants that showed a lower adherence than that 
of the wild type. These hits were organized according to their adherence patterns in Error! 
Reference source not found. below.  
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Table 1: List of Hits from Primary Screen with Descriptions, Organized According to Higher or Lower 
Adherence 
Adheres More Than WT 
PRN4 protein with similarity to pirins, flow model biofilm repressed 
CSA2 
Extracellular-associated protein; repressed by Rim101 at pH 8; regulated by Tsa1, 
Tsa1B in minimal media at 37 deg; induced by ketoconazole, nitric oxide, Hap43; 
required for normal RPMI biofilm formation; Bcr1 induced in RPMI 
ORF19.3919 RNI-like superfamily domain-containing protein; early-stage flow model biofilm 
induced; Spider biofilm induced 
LIP2 Secreted lipase; member of a differentially expressed lipase gene family; expressed 
in alimentary tract, but not oral tissue, during mouse oral infection; may have a role 
in nutrition and/or in creating an acidic microenvironment 
RBT5 
GPI-linked cell wall protein; hemoglobin utilization; Rfg1, Rim101, Tbf1, Fe 
regulated; Sfu1, Hog1, Tup1, serum, alkaline pH, antifungal drugs, geldamycin 
repressed; Hap43 induced; required for RPMI biofilms; Spider biofilm induced 
HAK1 
Putative potassium transporter; similar to Schwanniomyces occidentalis Hak1p; 
amphotericin B induced; induced upon phagocytosis by macrophage; Hap43-
repressed; rat catheter biofilm repressed 
HET1 
Putative sphingolipid transfer protein; involved in localization of glucosylceramide 
which is important for virulence; Spider biofilm repressed 
ORF19.6637 Predicted glycosyl hydrolase; hypoxia induced; flow model biofilm induced 
HEX1 Beta-N-acetylhexosaminidase/chitobiase, highly glycosylated enzyme that is 
secreted to the periplasm and culture medium; required for full virulence; may 
have role in carbon or nitrogen scavenging; possibly an essential gene (UAU1 
method) 
NPR2 Putative urea transporter; induced during infection of murine kidney, compared to 
growth in vitro; has murine homolog 
ORF19.587 Ortholog(s) have transcription export complex localization 
ORF19.649  
CFL11 
Protein similar to ferric reduc (Inglis DO, 2012)tase Fre10p; flucytosine repressed; 
possibly adherence-induced; possibly an essential gene, disruptants not obtained 
by UAU1 method; rat catheter biofilm repressed 
ORF19.2726 Putative plasma membrane protein; Plc1-regulated; Spider biofilm induced 
HYR1 
GPI-anchored hyphal cell wall protein; macrophage-induced; repressed by 
neutrophils; resistance to killing by neutrophils, azoles; regulated by Rfg1, Efg1, 
Nrg1, Tup1, Cyr1, Bcr1, Hap43; Spider and flow model biofilm induced 
Adheres Less than WT 
ORF19.380 Protein of unknown function; induced by alpha pheromone in SpiderM medium 
BTA1 Betaine lipid synthase  
ORF19.1365 
Putative monooxygenase; mutation confers hypersensitivity to toxic ergosterol 
analog; constitutive expression independent of MTL or white-opaque status 
HWP2 GPI-anchored, glycosylated cell wall protein; required for biofilm formation, 
adhesion, filamentous growth on some media; expressed in hyphae; mutant 
delayed in virulence; regulated by Efg1, Tup1; similar to Hwp1 and Rbt1 domains 
MTS1 Sphingolipid C9-methyltransferase; catalyzes methylation of the 9th carbon in the 
long chain base component of glucosylceramides; glucosylceramide biosynthesis 
is important for virulence; Spider biofilm repressed 
FLO9 Putative adhesin-like cell wall mannoprotein; repressed during the mating 
process; mutation confers hypersensitivity to toxic ergosterol analog; decreased 
transcription is observed upon fluphenazine treatment 
ORF19.5449 Predicted integral membrane protein; Spider biofilm induced 
PGA10 
GPI anchored membrane protein; utilization of hemin and hemoglobin for Fe in 
host; Rim101 at ph8/hypoxia/ketoconazole/ciclopirox/hypha-induced; required 
for RPMI biofilm formation, Bcr1-induced in a/a biofilm; rat catheter biofilm 
repressed 
KRE5 
UDP-glucose:glycoprotein glucosyltransferase; 1,6-beta-D-glucan biosynthesis, 
hyphal growth, virulence in mouse IV model; partially complements S. cerevisiae 
kre5 mutant defects; flow biofilm repressed, Bcr1-repressed in RPMI a/a biofilms 
ORF19.2484 Has domain(s) with predicted peptidase activity and role in proteolysis 
GZF3 
GATA-type transcription factor; oxidative stress-induced via Cap1; mutant has 
abnormal colony morphology and altered sensitivity to fluconazole, LiCl, and 
copper; Spider biofilm induced 
ORF19.3108 
Putative DNA repair methyltransferase; induced by nitric oxide independent of 
Yhb1; Spider biofilm induced 
ORF19.3226 
Ortholog(s) have role in intracellular sterol transport and extracellular region, 
fungal-type vacuole lumen localization 
HYR4 
Putative GPI-anchored adhesin-like protein; Rim101-repressed; constitutive 
expression independent of MTL or white-opaque status 
ORF19.3404 Protein of unknown function; transcription repressed by fluphenazine treatment 
ORF19.3763 Has domain(s) with predicted serine-type endopeptidase activity and integral to 
membrane localization 
GYP1 Putative Cis-golgi GTPase-activating protein; transcript regulated by Nrg1, Mig1, 
and Tup1 
KIS1 
Snf1p complex scaffold protein; similar to S. cerevisiae Gal83p and Sip2p with 
regions of similarity to Sip1p (ASC and KIS domain); interacts with Snf4p; mutants 
are hypersensitive to caspofungin and hydrogen peroxide; Hap43p-repressed 
gene 
ORF19.4195 
Ortholog of C. dubliniensis CD36 : Cd36_60540, C. parapsilosis CDC317 : 
CPAR2_602830, Candida tenuis NRRL Y-1498 : CANTEDRAFT_108530 and 
Debaryomyces hansenii CBS767 : DEHA2F15532g 
CAS5 
Transcription factor; cell wall damage response; required for adherence, 
response/resistance to caspofungin; repressed in core stress response; mutants 
have reduced CFU in mice, hyphal defect in C. elegans infection; Spider biofilm 
induced 
ORF19.4805 
Putative membrane protein; induced by alpha pheromone in SpiderM medium; 
Hap43-induced gene; Spider biofilm induced 
IFF11  
ORF19.5406  
PTC7 
Protein phosphatase, type 2C; has S/T phosphatase activity, Mn2+/Mg2+ 
dependent; predicted membrane-spanning segment and mitochondrion-targeting 
signal 
MBP1 
Putative component of the MBF transcription complex involved in G1/S cell-cycle 
progression; non-periodic mRNA expression; predicted, conserved MBF binding 
sites upstream of G1/S-regulated genes 
 Analysis of Pathways that Regulate Filastatin Action 
 
To identify genes and cellular components that regulate biological function of filastatin 
Gene Ontology (GO) analysis was performed (Inglis et al, 2012).This analysis showed that 
several genes were related in regards to the biological functions (such as metabolism, biofilm 
formation, etc) that they regulate. 7 of the 42 mutant genes identified were defined by the 
category “single species biofilm formation”, giving significance between 1E-4 and 0.5. 2 out of 
the 42 mutants fall under the category hemoglobin import, also showing the significance of 
1.0E-4 to 0.5. The results of this analysis can be viewed in Table 2 below.    
 
 
 
 
 
 
 
ORF19.6318 Ortholog(s) have endoplasmic reticulum, mitochondrion localization 
ORF19.6449  
ORF19.6654 Predicted membrane transporter, member of the L-amino acid transporter-3 
(LAT3) family, major facilitator superfamily (MFS) 
Table 2: CGD GO analysis results for Process Ontology (Inglis et al, 2012) 
Terms from the Process Ontology 
Gene 
Ontology 
term 
Cluster 
frequency 
Background 
frequency 
Corrected 
P-value 
False 
discovery 
rate 
Genes 
annotated to 
the term 
Hemoglobin 
import  
2 out of 42 
genes, 4.7% 
2 out of 6517 
background genes, 
0.0% 
0.00769 4.00% PGA10, RBT5 
Single-
species 
biofilm 
formation 
6 out of 42  
genes, 
14.0% 
132 out of 6517 
background genes, 
2.0% 
0.03674 6.00% CAS5, CSA2, 
HWP2, HYR1, 
PGA10, RBT5 
Biofilm 
formation  
6 out of 42 
genes, 
14.0% 
141 out of 6517 
background genes, 
2.2% 
0.05262 5.33% CAS5, CSA2, 
HWP2, HYR1, 
PGA10, RBT5 
 
GO analysis was also used to compare the cellular components of the genes of interest. 
Out of the 42 genes that were run through the Go analysis, six of the genes fell under external 
encapsulating structures with a significance of 1.0E-4 to 0.5. Another cellular component that 
showed a similar level of significance were genes that fell into the extracellular region, which 
encompassed seven of the forty two genes. The results of this analysis are shown in Table 3 
below.  
 
 
Table 3: CGD GO analysis results for Component Ontology (Inglis et al, 2012) 
Terms from the Component Ontology 
Gene 
Ontology 
term 
Cluster 
frequency 
Background 
frequency 
Corrected 
P-value 
False 
discovery 
rate 
Genes annotated to the 
term 
Extracellular 
region  
7 out of 42 
genes, 
16.3% 
133 out of 
6517 
background 
genes, 2.0% 
0.00105 2.00% CSA2, HEX1, HYR1, 
IFF11, LIP2, RBT5, 
orf19.3226 
Cell wall  6 out of 42 
genes, 
14.0% 
142 out of 
6517 
background 
genes, 2.2% 
0.01450 14.00% HWP2, HYR1, HYR4, 
IFF11, PGA10, RBT5 
Fungal-type 
cell wall  
6 out of 42 
genes, 
14.0% 
142 out of 
6517 
background 
genes, 2.2% 
0.01450 9.33% HWP2, HYR1, HYR4, 
IFF11, PGA10, RBT5 
External 
encapsulating 
structure  
6 out of 42 
genes, 
14.0% 
144 out of 
6517 
background 
genes, 2.2% 
0.01563 7.00% HWP2, HYR1, HYR4, 
IFF11, PGA10, RBT5 
 
Of the forty two hits that were found, 24% or 10 mutants were regulated by the 
transcription factor Hap43 and 12% were regulated by Rim101.  There is an overlap of 7% 
between these genes and which are thought to be regulated by both Hap43 and Rim101. These 
genes are organized graphically in the Venn diagram in Figure 6 below.  
 
 Figure 6: Genes Regulated by Hap43 and/or Rim101 
 
Validation of mutants identified 
Since a high number of hits were associated with both Hap43, a CCAAT-binding factor-
dependent transcription factor that is required for survival for low iron response, and Rim101, a 
transcription factor needed for alkaline-induced hyphal growth (Inglis et al, 2012), these two 
transcription factors were chosen for further analysis.  The knock out mutants of Hap43 and 
Rim 101 were selected for complementation to confirm that they play a role in the biological 
function of filastatin. The Rim101 knock out mutant (taken from the Noble Library) does not 
show the presence of filamentation when put through the Hyphal growth profiling experiments 
with the use of spider inducing media, when compared to the wild type SN250.  
The transcription factor knockout Hap43 has previously shown to have higher copper 
metal resistance than that of the wild type (Homann et al, 2009) and was chosen to test if the 
Regulated by Hap43 
• ORF 19.716 
• CSA2 
• KIS1 
• PGA7/10 
• RBT5 
• ARR3 
• ORF 19,4895 
• ORF 19.376 
• HYR1 
Regulated by 
Rim101 
• PGA7/10 
• RBT5 
• HYR4 
• CSA2 
Regulated 
by Both 
 RBT5 
 PGA7/10 
 CSA2 
complementation was successful. The Rim101 and Hap43 genes were then complemented back 
into their respective knockout mutants using the previously described method. Rim101 
complementation was checked using PCR and phenotypic analysis.  
  
Discussion: 
Our results have identified two pathways that may regulate filastatin activity. In our 
assay, we considered mutants that showed little to no decrease in adhesion in the presence of 
filastatin relative to the negative control to be ‘hits’ as described in Error! Reference source not 
found. above. The rationale was that if the mutant lacks a target of filastatin, then adding 
filastatin will have no effect on how well the fungi can adhere to the plastic. Therefore, the 
differences in absorbance between wells that have filastatin and those that do not will be 
statistically insignificant. If these values were within 10% of each other during the primary 
screen, we selected that strain for retesting in our secondary screen. Conversely, ‘non-hits’ 
were strains which showed significantly lower binding in the presence of filastatin in 
comparison to the negative control. In theory, these strains have deletions in genes that are 
unrelated to the targets of filastatin; as a result, filastatin is still capable of being effective and 
reducing adhesion and biofilm formation. Our screening produced 42 potential genes of 
interest, of which we focus on three: Rim101, Hap43 and PGA10.  
One gene that we believe may be a target of filastatin is Rim101 or one of the several 
pathways which it regulates. Rim101 has been previously shown to regulate gene expression 
responses to extracellular changes in pH. Specifically, Rim101 has been shown to induce hyphal 
formation in response to neutral or alkaline pH conditions. In addition, this gene is known to be 
a member of the Rim101/PacC family of C2H2 zinc finger transcription factors, which play a 
number of different roles in regulating the virulence of different fungal pathogens (Penalva and 
Arst, 2004). A number of studies have been performed showing the role of Rim101 in hyphal 
formation and the fungal virulence. One study found that Rim101 mutants formed shorter and 
fewer true hyphae but more pseudohyphae in comparison to the wild type. The same study 
also looked at the ability of a Rim101 mutant to invade oropharyngeal epithelial cells. It has 
been previously known that Candida albicans invades this particular type of epithelial cell by 
damaging them and inducing their own endocytosis. However, mutants lacking Rim101 have a 
significantly decreased capability of being endocytosed by epithelial cells, which suggests that 
Rim101 plays an important role in initiating infections of the epithelia. Lastly, mice infected 
with Rim101 mutants had significantly lower fungal burden levels than mice infected with the 
wild type or with strain in which the Rim101 gene was complemented. Therefore, these studies 
show that this gene plays an important role in the initiation of infection by C. albicans in 
epithelial cells. One current hypothesis regarding the exact role of Rim101 in virulence is that it 
is responsible for activating and regulating hyphae-specific genes.  In fact, it has been found 
that many of the most Rim101-dependent genes, such as SOD5, CSA2, PGA7/RBT6, ECE1, CSA1, 
SAP5, HYR1 and RBT5 are specific to hyphae formation. Our drug filastatin has been previously 
shown to inhibit hyphal formation in C. albicans in both biotic and abiotic environments. 
Therefore, one hypothesis explaining the effects of filastatin is that it could interact with 
Rim101 or one of the hyphal-specific genes that it regulates, thereby inhibiting the formation of 
hyphae. Furthermore, Rim101 is known to also regulate genes that play a role in biofilm 
adherence, such as Pga10 and Csa1. Therefore, it is also possible that filastatin may inhibit the 
formation of biofilms by disrupting one of these pathways as well. Currently, more tests are 
needed to determine whether or not filastatin has an effect on Rim101 or any of its pathways 
(Nobile, et al., 2008). 
Of all of the genes of interest identified in the screen, a significant portion of them were 
found to be regulated by a transcription factor known as Hap43. Hap43 has previously been 
indicated in iron-metabolism due to the fact that mutants lacking Hap43 were unable to survive 
on iron-deficient media. However, Hap43 mutants displayed a normal ability to uptake iron in 
various assays, suggesting that Hap43 does not play a major role in iron acquisition but rather 
iron utilization. Quantitative gene analysis revealed that Hap43 is actually responsible for 
repressing genes that utilize iron under iron deprivation and upregulating iron acquisition 
genes. Most significantly, however, Hap43 mutants were shown to be considerably less virulent 
in comparison to the wild-type or heterozygotes in a mouse model of disseminated candidiasis. 
It has been long known that the human body (and mice) has extremely low concentrations of 
free-ionic iron in order to promote proper functioning of the immune system and to inhibit the 
growth of pathogens. Therefore, this suggests that the iron metabolism pathways regulated by 
Hap43 also play a critical role in fungal virulence. Because Hap43 has been shown to regulate 
many of our genes of interest, this seems to suggest that filastatin may play a role in disrupting 
the fungi’s ability to survive and switch to its virulent form in low iron conditions (Hsu, et al., 
2011).  
By focusing on our hypothesis that filastatin affects adhesion and virulence via 
disruption of C. albicans’ iron metabolism pathways, we identified PGA10 (which is also known 
as RBT51) as a particular gene of interest. During our screening process, we found that PGA10 
was one of three genes that were regulated by Hap43 and Rim101 that was known to play a 
role in iron-acquisition and metabolism. In particular, PGA10 has been found to be especially 
important in hemin and hemoglobin-iron acquisition. C. albicans mutants containing a deletion 
of PGA10 showed no growth on media in which hemoglobin was the only available iron source; 
however, when the PGA10 gene was complemented back into the mutant, the wild type 
phenotype was fully restored. In addition, heterozygotes for this gene demonstrated a reduced 
growth pattern on this type of media, suggesting a haploinsufficiency of strains possessing a 
single copy of the gene. PGA10 has also been shown to be induced in conditions of iron-
starvation; considering that several of the genes we found in our screening played a role in iron 
acquisition, this finding further strengthens our hypothesis that filastatin disrupts one or more 
iron metabolism pathways in the cell. Lastly, PGA10 has been shown to be a glycoprotein that 
localizes at the cellular envelope due to the presence of a GPI consensus sequence at its C-
termini and a predicted signal sequence at its N-termini (Weissman and Kornitzer, 2004). By 
utilizing this knowledge, we were able to suggest a potential hypothesis as to how filastatin 
works, which is summarized below in Figure 99. We suggest that filastatin and hemoglobin 
compete for binding sites on PGA10 at the surface of cells. In low-iron conditions, PGA10 is 
upregulated and expressed via Rim101 and Hap43 in order to acquire hemoglobin from its 
surroundings. Binding triggers the endocytosis of hemoglobin and PGA10 into the cell along 
with initiating signal transduction pathways (which are currently unknown to us) that induce 
hyphal growth and other virulence factors. In addition, several PGA10 receptors from different 
C.albicans cells can bind to a single molecule of hemoglobin. Therefore, a relatively large 
number of yeast cells are capable of binding to a small number of hemoglobin complexes. As a 
result, the cells begin to aggregate and form sheets as they begin to create an extracellular 
matrix. We speculate that filastatin disrupts the binding of PGA10 to hemoglobin. If this were 
the case, the presence of filastatin would prevent C. albicans from agglomerating into biofilms. 
We hypothesize that filastatin disrupts the binding of hemoglobin to PGA10, thereby inhibiting 
iron-acquisition, biofilm formation and other virulence factors. However, additional evidence is 
required before this hypothesis can be supported. A number of different assays that can be 
performed in the future in order to better understand the mechanism of filastatin will be 
discussed in detail later in this report. 
 
 
 
 
 
 
 
Though this proposed mechanism would explain how filastatin disrupts the formation of 
biofilms in vivo, it does not explain how filastatin can prevent and reverse biofilm on abiotic 
surfaces such as polystyrene. It is possible that this may not be the exact mechanism that 
filastatin utilizes or that filastatin may perform its function through a number of different 
pathways. Therefore, a number of different experiments should be performed to thoroughly 
elucidate the mechanism of action of filastatin in both biotic and abiotic environments. In 
addition, it may be necessary to perform a screen using another deletion library to study the 
effect of filastatin on non-transcription factor mutants. 
Figure 7: Example of a possible single target interaction with PGA10, which is regulated by Hap43 
There a number of experiments that should be performed in the future to better 
understand the mechanism of filastatin. To test our PGA10 hypothesis mentioned earlier, it 
may be beneficial to observe whether or not adding varying concentrations of hemoglobin in 
the presence of filastatin would be able to restore adhesion and biofilm formation capability to 
the wild type, SN250. Our hypothesis states that filastatin disrupts binding of PGA10 to 
hemoglobin, which in turn prevents cells from adhering to each other and forming biofilms. If 
this were true, adding hemoglobin should, in theory, lower the probability of filastatin binding 
to PGA10. As a result, this would restore the ability of Candida to agglomerate and form 
biofilms. One potential experimental model would be to use a double gradient; for example the 
concentration of filastatin could be varied down a single row on a 96 well plate while 
hemoglobin concentration could be varied down a single column. This set up would make it 
possible to study the effect of both hemoglobin and filastatin at a number of different 
concentrations. If our hypothesis is true, we would predict that as the concentration of 
hemoglobin is increased at a particular concentration of filastatin, binding of Candida to 
polystyrene should increase. Conversely, at low levels of hemoglobin and high levels of 
filastatin we would expect adhesion levels to be very low. This assay alone would not be able to 
strongly support our hypothesis; a number of additional experiments would also be needed 
improve our understanding of the relationship between PGA10, filastatin and hemoglobin. For 
example, a similar assay could be performed using iron (II) or iron (III) to determine if filastatin 
disrupts the interaction between PGA10 and the entire hemoglobin complex or only the central 
iron atom. 
In order to better understand and further validate the hits of interest that were found 
through our primary screening, it will be important to compliment and rescue the phenotypes 
that have been seen through the screening. This will involve taking some of the more promising 
candidates and using the previously described complementation protocol to place the gene of 
interest back into the genome at a highly expressed region. Then, the adhesion assay would 
need to be revisited, to show that to a degree of upmost certainty, the mutants that we are 
interested in are causing the phenotype exhibited. 
            After the knocked out gene has been replaced in the mutant’s genome, further testing 
can be done to help further validate the authenticity of our results. There are a variety of tests 
and possibilities for future testing, ranging from in vivo and in vitro.  One possible test at the in 
vivo level could be the use of a C. elegans survival assay with the use of our complimented 
strains and knockouts. This type of testing would be helpful in gaining a better understanding of 
how our knockouts and complemented strains affect a multi-cellular organism.  Another 
possible experiment set to explore would be the use of an in vitro biofilm growth assay to gain a 
better understanding of how our knockouts adhere to silicone, which is similar to the material 
of implanted medical devices (Fazly, et al., 2013). This MQP has shown much promise into 
gaining a further understanding of how filastatin functions; with further testing these promising 
leads can be further validated. 
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